Uvax Bio LLC, a vaccine biotechnology company based on the single-component self-assembling protein nanoparticle (1c-SApNP®) vaccine design and manufacturing platform invented by Associate Professor Jiang Zhu, PhD, of Scripps Research (La Jolla, CA) today announced that Cheryl Keech, MD, Ph.D., has joined the company as… [Read more]
Uvax-2129, a recombinant protein nanoparticle vaccine, as Uvax Bio’s answer to COVID-19, shows great promise against multiple variants of concern. Result of a research work funded by the National Institutes of Health and by Uvax Bio LLC published in Science Advances on October 20, 2021… [Read more]
About Uvax Bio
Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.
Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.